Anti-IL5/IL5R use was associated with a significantly lower risk of mortality (aHR 0.35, 95% CI 0.29–0.42), congestive heart failure (aHR 0.63, 95% CI 0.52–0.76), arrythmia (aHR 0.78, 95% CI 0.68–0.90), and peripheral artery disease (aHR 0.69, 95% CI 0.54–0.87) compared with non-biologic users. This evidence concerns the gene IL5RA and peripheral arterial disease.